Skip to main content
SpringerLink
Log in

Cytokine-based biotherapy of gastrointestinal tumors

  • Clinical Pharmacology
  • Published:
The clinical investigator Aims and scope Submit manuscript

Abstract

Over the past 20 years the administration of cytokines has emerged as an important fourth modality for the treatment of human cancer. Advances in the field of therapy of gastrointestinal tumors have become a major focus of current research, given the lack of progress of conventional antineoplastic therapy in most of these tumors. Among the heterogeneous group of gastrointestinal malignancies, novel therapeutic strategies have been employed for each individual tumor type, and cytokines (interferon-a) have gained an established role in the treatment of advanced carcinoid tumors. Although our understanding of the mechanisms of biological response modification is still limited, further improvement in the management of gastrointestinal malignancies can be expected from multimodality therapy regimens employing cytokines in combination with other biological response modifiers, chemotherapeutic agents, active-specific immunotherapy, and immunotoxin- and radionuclide-conjugated monoclonal antibodies. A wide range of clinical and preclinical studies have been conducted in colorectal carcinoma; however, potential therapeutic benefit of cytokine-based biotherapy has not been fully defined. Therefore, large-scale, i.e., multicenter, studies are required to quantify the potential therapeutic effects of cytokines in gastrointestinal tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

FA:

folinicacid

5-FU:

5-fluorouracil

GI:

gastrointestinal

HCC:

hepatocellular carcinoma

IFN:

interferon

IL:

interleukin

LAK cells:

lymphokineactivated killer cells

TNF:

tumor necrosis factor

References

  1. Abbruzzese JL, Levin B, Ajani JA, Faintuch JS, et al (1990) A phase 11 trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Modif 9:522–527

    Google Scholar 

  2. Ajani JA, Rios AA, Ende K, et al (1989) Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluouracil in patients with advanced colorectal carcinoma. J Biol Response Modif 8:140–146

    Google Scholar 

  3. Arinaga S, Karimini N, Takamuka K, Nanbara S, Akiyoshi T (1992) Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin-C. Cancer Immunol Immunother 35:246–250

    Google Scholar 

  4. Arinaga S, Karimine N, Takamuka K, Nanbara S, Akiyoshi T (1992) Enhanced induction of LAK activity after lentinan administration in patients with gastric carcinoma. Int J Immunopharmacol 14:535–539

    Google Scholar 

  5. Atzpodien J, Korfer A, Evers P, Franks CR, Knüver-Hopf J, Lopez-Hänninen E, Fischer M, Mohr H, Dallmann I, Hadam M, Poliwoda H, Kirchner H (1990) Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 2:18–26

    Google Scholar 

  6. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-a2b in advanced human malignancies. Lancet 335:1509–1512

    Article  CAS  PubMed  Google Scholar 

  7. Atzpodien J, Kirchner H, Körfer A, Menzel T, Schomburg A, Poliwoda H (1994) Treatment of metastatic colorectal cancer patients with 5-fluouracil in combination with recombinant subcutaneous human interleukin-2 and interferon-α. Oncology 51:273–275

    Google Scholar 

  8. Biesma B, Willemse PHB, Mulder NH, Verschueren RCJ, Kema IP, de Bruijn HWA, Postmus PE, Sleijfer DT, de Vries EGE (1992) Recombinant interferon-alpha 2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer 66:850–855

    Google Scholar 

  9. Blottiere HM, Douillard JY, Koporowski H, Steplewski Z (1990) Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon-gamma. Cancer Immunol Immunother 32:29–37

    Google Scholar 

  10. Brown T, Tangen C, Fleming T, Macdonald J (1993) A phase II trial of taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc ASCO 12:200

    Google Scholar 

  11. Brunetti I, Falcone A, Giannessi P, et al (1991) Double 5-fluorouracil modulation with folinic acid and alfa-2b interferon in metastatic colorectal carcinoma patients. Proc AACR 32:92

    Google Scholar 

  12. Bukowski RM, Inoshita G, Yalavarthi P, Murthy S, Gibson V, Budd GT, Sergi JS, Bauer MS, Prestifilippo J (1992) A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. Cancer 69:889–892

    Google Scholar 

  13. Cascinu S, Fedeli A, Fedeli SL, Catalano G, Luzi S (1992) Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon-alfa-2b in advanced colorectal cancer. Ann Oncol 3:489–491

    Google Scholar 

  14. Chou T, Chang AE, Shu S (1988) Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. J Immunol 140:2453–2461

    Google Scholar 

  15. Chu E, Zinn S, Allegra C (1991) Translation regulation of thymidilate synthase in response to 5-fluorouracil and gamma-interferon in a human colon cancer cell line. Proc AACR 32:489–491

    Google Scholar 

  16. Creutzfeldt W, Bartsch HH, Jacubaschke U, Stöckmann F (1991) Treatment of gastrointestinal endocrine tumors with interferon-α and octreotide. Acta Oncol 30:529–535

    Google Scholar 

  17. Crown J, Jakubowski A, Kemeny N, Gordon M, et al (1991) A phase I trial of recombinant interleukin-1b alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 78:1420–1427

    Google Scholar 

  18. Derderian P, Pazdur R, Ajani J, et al (1991) Phase II study of 5-fluorouracil and recombinant interferon-alpha-2a in the treatment of advanced pancreatic carcinoma. Proc AACR 10:147

    Google Scholar 

  19. DeVita VT, Hellmann S, Rosenberg SA (eds) (1991) Biologic therapy of cancer. Lippincott, Philadelphia

    Google Scholar 

  20. Diaz-Rubio E, Jimeno J, Camps C, Aranda E, Massati B, Blanco E, Anton A, Lizon J (1992) Treatment of advanced colorectal cancer with recombinant alpha-interferon and fluorouracil. Cancer Invest 10:259–264

    Google Scholar 

  21. DiBartolomeo M, Zilembo N, Castellani R, Tinessa V, Bajetta E (1991) Interferon-alpha-2a in carcinoid and other neuroendocrine tumors. Proc AACR 32:312

    Google Scholar 

  22. Dirix JY, Prove A, Fierens H, VanOosterom AT (1991) Alpha-interferon treatment of metastatic carcinoid tumors. Proc AACR 32:312

    Google Scholar 

  23. Douillard JY, Leborgne J, Danielou JY, et al (1991) Phase II trial of 5-fluorouracil and recombinant interferon-alpha in metastatic, previously untreated colorectal cancer. Proc ASCO 10:139

    Google Scholar 

  24. Elias L, Crissman HA (1988) Interferon effects on the adenocarcinoma 38 and HL-60 cell lines. Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res 48:4868–4873

    Google Scholar 

  25. Elias L, Sandoval JM (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:864–867

    Google Scholar 

  26. Findlay M, Hill A, Cunningham D, Norman A, Nicolson M, Ford H, Husband J, Evans C, Carter R (1994) Protraced venous infusion 5-fluorouracil and interferon-a in advanced and refractory colorectal cancer. Ann Oncol 5:239–243

    Google Scholar 

  27. Gabrilove J, Jakubowski A, Crown J, et al (1991) A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Ann Hematol 6:99

    Google Scholar 

  28. Gandolfi L, Solmi L, Pizza CG, et al (1989) Intratumoral echo-guided injection of interleukin-2 and LAK cells in hepatocellular carcinoma. Hepatogastroenterology 36:352–356

    Google Scholar 

  29. Gomez J, Pazdur R, Ajani J, et al (1991) Phase II study of 5-fluorouracil and recombinant alpha-2a-interferon in the treatment of advanced gastric carcinoma. Proc ASCO 10:147

    Google Scholar 

  30. Hamblin TJ, Inzani V, Sadullah S, et al (1989) A phase II trial of recombinant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal cancer. Cancer Treat Rev 16:163–167

    Google Scholar 

  31. Hansen R, Schurtz M, Vukelich M, Blake D, Anderson T (1991) A phase II study of 5-fluorouracil infusion, interferon-alpha, and dipyridamole in advanced colorectal cancer. Proc ASCO 10:154

    Google Scholar 

  32. Hansmann E, Grnntjens-Prinsen G, Bremer K, Linnemann G (1991) Additional modulation of 5-fluorouracil by interferon-alpha-2b in advanced colorectal cancer refractory to 5-FU and folinic acid. Proc AACR 32:93

    Google Scholar 

  33. Hayakawa K, Fukushima T, Seito D, Asakura Y, Yamanaka Y, Morita T, Sasaki M, Konn M, Ono K (1989) Continuous arterial infusion therapy of recombinant interleukin-2 and cyclophosphamide in liver metastasis. Gan To Kagaku Ryoho 16:2842–2844

    Google Scholar 

  34. Hiddemann W, Ruelfs C, Ottensmeier C, Ruckle H, Musch E, Koch O, van de Loo J (1992) Interleukin-2 followed by 5-fluorouracil and folinic acid in refractory colorectal cancer — results of a phase II study. Semin Oncol 19:225–227

    Google Scholar 

  35. Huberman M, McLay E, Atkins M, Goldsweig H, Bonanno D, Layton M, Tessitore J (1991) Phase II trial of 5-fluorouracil and recombinant interferon-alpha-2a in advanced colorectal cancer. Proc ASCO 10:153

    Google Scholar 

  36. Iaffaioli RV, Frasci G, Facchini G, et al (1991) Neoadjuvant immunotherapy in locally advanced gastric cancer. Proc AACR 32:77

    Google Scholar 

  37. Israel L, Boaziz C, Moliard M, Morere JF, Breau JL (1991) Phase II study of interleukin-2 in 18 patients with advanced gastrointestinal tract cancers. Proc ASCO 10:139

    Google Scholar 

  38. Jäger-Arand E, Bernhard H, Klein O, Wächter B, Dippold W, Meyer z Büschenfelde KH, Knuth A (1993) Combination 5-fluorouracil (FU), folinic acid (FA) and α-interferon 2b (IFN) in advanced gastric cancer. Proc ASCO 12:192

    Google Scholar 

  39. Jaiyesimi I, Pazdur R, Patt YZ, et al (1991) Phase II study of recombinant inteferon-alpha-2a and continuous infusion 5-fluorouracil in metastatic colorectal carcinoma. Proc ASCO 10:147

    Google Scholar 

  40. Kalofonos HP, Gogos H, Vasiliou V, Karatza C (1991) Interferon alpha and cyproterone acetate in the treatment of primary hepatocellular carcinoma. Proc AACR 32:226

    Google Scholar 

  41. Kawata A, Uchino J, Une Y, et al (1991) Early postoperative chemoimmunotherapy with adriamycin, rIL-2 and spleen derived LAK cells for hepatocellular carcinoma patients. Proc AACR 32:251

    Google Scholar 

  42. Kelsen D, Lovett D, Wong J, et al (1992) Interferon-alpha-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 10:269–274

    Google Scholar 

  43. Kemeny N, Younes A, Seiter K (1992) Interferon-alpha-2a and 5-fluorouracil for the advanced colorectal cacinoma: the Memorial Sloan-Kettering experience. Semin Oncol 19:171–175

    Google Scholar 

  44. Knuth A, Bernhard H, Klein O, Meyer z Büschenfelde KH (1992) Combination of 5-fluorouracil, folinic acid, and interferon-alpha-2a: an active regimen in advanced pancreatic cancer. Semin Oncol 19:211–214

    Google Scholar 

  45. Köhne-Wömper CH, Schmoll HJ, Hiddemann W, et al (1992) 5-Fluorouracil, folinic acid, alpha-2b-interferon in advanced colorectal cancer. Ann Oncol 1:195

    Google Scholar 

  46. Komatsu T, Ymauchi K, Furukawa T, Obata H (1990) Transcatheter arterial injection of autologous lymphokine-activated killer cells into patients with liver cancers. J Clin Immunol 10:167

    Google Scholar 

  47. Kreuser ED, Hilgenfeld RU, Matthias M, Hoksch B, Oldenkott B, Porzsolt F, Disel W (1992) A phase II trial of interferon-alpha-2b with folinic acid and 5-fluorouracil administered by 4 hour infusion in metastatic colorectal cancer. Semin Oncol 19:57–62

    Google Scholar 

  48. Labianca R, Pancera G, Tedeski L, Dallavalle G, Luporini G (1992) High dose alpha 2b-interferon and folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavorable cost/benefit ratio. Tumori 78:32–34

    Google Scholar 

  49. Lee KH, Lee JS, Suh C, Lee YS, Min YI, Ahu SH, Park UH, Kim SK (1992) Combination of 5-fluorouracil and recombinant alpha-2b-interferon in advanced gastric cancer. Am J Clin Oncol 15:141–145

    Google Scholar 

  50. Lotz JP, Grange JD, Hannoun L, et al (1991) Treatment of unresectable hepatocellular carcinoma with alpha-2b interferon and doxorubicin. Proc AACR 32:73

    Google Scholar 

  51. Lovett D, Kelsen D, Heelan R (1990) 5-Fluorouracil and alpha-interferon in the treatment of esophageal carcinoma. Proc ASCO 9:121

    Google Scholar 

  52. Matheson DS, Green BJ, Friedman SJ, Hoar DI (1988) Studies on the mechanism of activation of human natural killer function by interferon. Cell Immunol 111:118–125

    Google Scholar 

  53. Mattioli R, Manocchi P, Pilone A, et al (1991) Mitomycin + 5-fluorouracil + folinic acid in association with alpha-2b-interferon in advanced colorectal cancer. Proc AACR 32:92

    Google Scholar 

  54. Merrouche Y, Negrier S, Rebattu P, et al (1991) A phase II study of interleukin-2 following high dose BCNU and autologous bone marrow transplantation in the treatment of metastatic gastric cancer. Proc ASCO 10:161

    Google Scholar 

  55. Mittelman A, Savona S, Gafney E, et al (1989) Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer cell infusions and recombinant human interleukin-2. J Bio Response Modif 8:468–478

    Google Scholar 

  56. Modiano M, Taylor C, Brooks R, Wiggins C, Power J, Alberts D (1993) Etoposide (E), leucovorin (L), 5-fluorouracil (F), and interferon-a2a (I) (ELFI) is an active treatment for high-risk or advanced pancreatic or gastric adenocarcinoma. Proc ASCO 12:203

    Google Scholar 

  57. Monden T, Morimoto H, Shimano T, et al (1992) Use of fibrinogen to enhance the antitumor effects of OK-432. A new approach to immunotherapy for colorectal carcinoma. Cancer 69:636–642

    Google Scholar 

  58. Moertel CG (1978) Chemotherapy of gastrointestinal cancer. New Engl J Med 299:1049–1052

    Google Scholar 

  59. Nio Y, Ohgaki K, Tsuchitani T, et al (1989) Oral administration of OK-432: its immunomodulatory effects on patients with gastrointestinal cancers. Nippon Gan Chiryo Gakkai Shi 24:1607–1615

    Google Scholar 

  60. Nobile MT, Sobrero A, Guglielmi A, et al (1991) Five-fluorouracil and leucovorin and interferon-alpha-2b in advanced colorectal cancer. Proc AACR 32:89

    Google Scholar 

  61. Öberg K, Erikson B (1991) The role of interferons in the management of carcinoid tumours. Br J Haematol 79:74–77

    Google Scholar 

  62. O'Connell MJ, Ritts RA, Moertel CG, Schutt AJ, Sherwin SA (1989) Recombinant interferon-gamma lacks activity against metastatic colorectal cancer. Cancer 63:1998–2004

    Google Scholar 

  63. Onodera H, Somers SS, Guillou PJ (1990) Paradoxical effects of 5-FU/folinic acid on lymphokine activated killer (LAK) cell induction in patients with colorectal cancer. Br J Cancer 62:1042–1046

    Google Scholar 

  64. Order SE, Stillwagon GB, Klein JL (1985) Idoine-131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group Study. J Clin Oncol 3:1573–1582

    Google Scholar 

  65. Patt Y, Noonan C, Pazdur R, et al (1991) Phase II trial of 5-fluorouracil and recombinant interferon-alpha in hepatocellular carcinoma. Proc ASCO 10:144

    Google Scholar 

  66. Patt YZ, Yoffe B, Charnsangavej C, Pazdur R, Fischer H, Cleary K, Roh M, Smith R, Noonan CA, Levin B (1993) Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 72:2574–2582

    Google Scholar 

  67. Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, Levin B (1992) A phase II trial of 5-fluorouracil and recombinant interferon-alpha in previously untreated metastatic gastric cancer. Cancer 69:878–882

    Google Scholar 

  68. Pazdur R, Moore DF, Bready B (1992) Modulation of 5-fluorouracil with recombinant alpha-interferon: M.D. Anderson clinical trial. Semin Oncol 19:176–179

    Google Scholar 

  69. Piedbois P, Gimonet JF, Feuilhade F, et al (1991) 5-Fluorouracil, folinic acid and alpha-2a-interferon combination in advanced gastrointestinal cancer. Proc ASCO 10:141

    Google Scholar 

  70. Preiss J (1992) 5-fluorouracil plus interferon-alpha2a and folinic acid in regional and systemic therapy in colorectal cancer. Semin Oncol 19:220–224

    Google Scholar 

  71. Punt CJA, Burghouts JTM, Croles JJ, vanLiessum PA, deMulder PHM, Kamm Y (1993) Continous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. Cancer 72:2107–2111

    Google Scholar 

  72. Reid I, Lundy J, Monson JRT, et al (1992) Heteroconjugated antibodies enhance lymphocyte-mediated tumour lysis in vitro and in vivo. Br J Surg 79:628–632

    Google Scholar 

  73. Reiter Z, Ozes ON, Blatt LM, Taylor MW (1992) A dual anti-tumor effect of a combination of interferon-α or interleukin-2 and 5-fluorouracil on natural killer cell-mediated cytotoxicity. Clin Immunol Immunopathol 62:103–111

    Google Scholar 

  74. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. NEJM 316:889–897

    Google Scholar 

  75. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Steinberg S, White DE (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863–1874

    Google Scholar 

  76. Rustum YM (1991) Rational basis for the metabolic modulation of 5-fluorouracil by leucovorin and interferon-alpha. Br J Haematol 19:52–55

    Google Scholar 

  77. Saleh MN, Khazaeli MB, Grizzle WE, Wheeler RH, Lawson S, Liu T, Russel C, Meredith R, Schlom J, LoBuglio AF (1993) A phase I trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. Cancer Res 53:4555–4562

    Google Scholar 

  78. Schmiegel WH, Bützow GH, Lanwieler T (1988) Biological response modifier in pancreatic cancer: clinical phase one trial with recombinant human tumor necrosis factor. Digestion 40:114

    Google Scholar 

  79. Schmoll HJ, Köhne-Wömper CH, Hiddemann W, Knipp H, Wilke H, Bodenstein H, Harstrick A, Hill H (1992) Interferon-alpha2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial. Semin Oncol 19:191–196

    Google Scholar 

  80. Schöber C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M, Bokemeyer C, Wilke H, Weiss J (1992) Antitumor effect and symptomatic control with interferon-alpha2b in patients with endocrine active tumors. Eur J Cancer 28:1664–1666

    Google Scholar 

  81. Schoof DD, Gramolini BA, Davidson DL, Eberlein TJ, et al (1988) Adoptive immunotherapy of human cancer using low-dose recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48:5007–5010

    Google Scholar 

  82. Schüller J, Czejka M, Miksche M, Fogl U, Jäger W (1991) Influence of interferon-alpha2b with or without leucovorin on pharmacokinetics of 5-fluorouracil. Semin Oncol 2:93–97

    Google Scholar 

  83. Sobrero A, Nobile MT, Gulglielmi A, Mori A, Schele C, Bolli E, Tixi L, Gallo L, Parodi GE, Bruzzi P (1992) Phase II study of 5-fluorouracil plus folinic acid and interferon-alpha2b in advanced colorectal cancer. Eur J Cancer 28:850852

    Google Scholar 

  84. Sporn JR, Buzaid A, Slater D, Greenberg BR (1993) Treatment of advanced pancreatic cancer with cisplatin, 5-FU, leucovorin, and interferon α-2b. Proc ASCO 12:207

    Google Scholar 

  85. Steger GG, Mader RM, Djavanmard MP, Gnant MFX, Locker G, Marosi C, Rainer H, Jakesz R (1994) Double modulation of 5-fluorouracil by high-dose leucovorin and interferon a2b in advanced colorectal caner: a phase I and a phase II study of weekly administration. J Cancer Res Clin Oncol 120:314–318

    Google Scholar 

  86. Steis RG, Urba WJ, VanderMolen LA, et al (1990) Intraperitoneal lymphokine-activated killer cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J Clin Oncol 8:1618–1629

    Google Scholar 

  87. Stolfi RL, Martin DS (1985) Modulation of chemotherapeutic drug activity with polyribonucleotides or with interferon. J Biol Response Modif 4:634–639

    Google Scholar 

  88. Strack M, Wadler S, Lyver A (1990) Phase II trial of fluorouracil and recombinant alpha-2a-interferon in patients with advanced carcinoma of the esophageus. Proc ASCO 9:119

    Google Scholar 

  89. Takagi K, Fukushima Y, Takano M, et al (1992) Exogenous and endogenous TNF therapy for advanced colorectal cancer. Ann Oncol 1:167

    Google Scholar 

  90. TakekoshiH, Yoshida K, Moringa S (1992) Immunochemotherapy of carcinomtous peritonitis and pleuritis. Gan To Kagaku Ryoho 19:1466–1469

    Google Scholar 

  91. Taleghani BM, Porowski P, Klink M, Gunzer U (1991) Interleukin-2 and alpha-interferon sc in combination with 5-fluorouracil and folinic acid iv in advanced progressive colorectal cancer. Ann Hematol 6:126

    Google Scholar 

  92. Tang ZY, Liu KD, Bao YM, et al (1990) Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second look resection. Cancer 65:211–215

    Google Scholar 

  93. The Gastrointestinal Tumor Study Group (1990) A prospective trial of recombinant human interferon-alpha-2b in previously untreated patients with hepatocellular carcinoma. Cancer 66:135–139

    Google Scholar 

  94. Tsugita M, Yamauchi K, Komatsu T, Suzuki H, Hanyu F (1990) Induction and clinical utilization of lymphokine-activated killer cells in patients with gastrointestinal tract cancers. J Gastroenterol Hepatol 5:110–115

    Google Scholar 

  95. Ubhi SS, Hollingworth J, Horsburgh T, Veitch PS, Franks CR, Bell PR (1992) Evaluation of the safety of recombinant interleukin-2 and recombinant interleukin-2 plus 5-fluorouracil in the adjuvant treatment of gastric carcinoma patients. Anticancer Res 12:749–752

    Google Scholar 

  96. VonHoff DD, Fleming TR, MacDonald JS, et al (1990) Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma. J Biol Response Modif 9:584–587

    Google Scholar 

  97. Wadler S, Wiernik PH (1990) Clinical update on the role of fluorouracil and recombinant interferon-alpha-2a in the treatment of colorectal carcinoma. Semin Oncol 17:16–21

    Google Scholar 

  98. Wadler S, Schwartz EL, Goldman M, et al (1989) Fluorouracil and recombinant alpha-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7:1769–1775

    Google Scholar 

  99. Wadler S (1991) The role of immunotherapy in colorectal cancer. Semin Oncol 18:27–38

    Google Scholar 

  100. Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N (1991) Phase II trial of fluorouracil and recombinant interferon-alpha-2a in patients with advanced colorectal carcinoma. J Clin Oncol 9:1806–1810

    Google Scholar 

  101. Weh HJ, Platz D, Braumann D, et al (1991) Treatment of metastatic colorectal carcinoma with 5-fluorouracil and interferon-alpha-2b. Proc AACR 32:93

    Google Scholar 

  102. Weiner LM, Steplewski Z, Koprowski H, Herlyn DM (1986) Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17–1A administration in patients with gastrointestinal carcinoma. Hybridoma 5:65–77

    Google Scholar 

  103. Weiner LM, Haller DG, Kirkwood J, et al (1991) Phase II trial of repetitive murine monoclonal antibody therapy in pancreatic carcinoma. Proc ASCO 10:161

    Google Scholar 

  104. West WH, Tauer KW, Yannelli JR, Marshall GD, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl J Med 316:898–905

    Google Scholar 

  105. Zaniboni A, Marpicati P, Simoncini E, et al (1991) Fluorouracil, high dose folinic acid, low-dose alpha-2b-interferon and dipyridamole in the treatment of advanced colorectal cancer. J Chemother 3:180–182

    Google Scholar 

  106. Ziegler LD, Palazzolo P, Cunningham J, Janus M, Itch K, Hayakawa K, Murray JL (1992) Phase I trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 10:1470–1478

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Hämatologie und Onkologie, Medizinische Hochschule Hannover, D-30623, Hannover, Germany

    J. Buer, H. Kirchner, A. Schomburg, E. Lopez-Hänninent, S. Duensing, H. Poliwoda & J. Atzpodien

  2. Abteilung Gastroenterologie und Hepatologie, Medizinische Hochschule Hannover, D-30623, Hannover, Germany

    A. Schüler & M. Manns

Authors
  1. J. Buer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Kirchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Schomburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Schüler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Manns
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Lopez-Hänninent
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Duensing
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Poliwoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. Atzpodien
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Correspondence to: J. Atzpodien

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buer, J., Kirchner, H., Schomburg, A. et al. Cytokine-based biotherapy of gastrointestinal tumors. Clin Investig 72, 526–534 (1994). https://doi.org/10.1007/BF00207483

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00207483

Key words

Search

Navigation